Challenges in inclusion

Venous thromboembolic disease (VTE) is a frequent and potentially serious pathology. Therapeutic management has improved considerably over the last few decades, enabling the application of codified management in line with the recently updated French management recommendations.

One of the main remaining difficulties concerns VTE sequelae, mainly post-thrombotic syndrome after deep vein thrombosis, and post-pulmonary embolism syndrome after pulmonary embolism. The mechanisms leading to the absence of complete repermeabilization of vessels affected by Venous thromboembolic disease (VTE) are still poorly understood.

The concept of immunothrombosis, closely associating immunity, inflammation and thrombosis, could (in part) explain the appearance of these sequelae. Platelets appear to play a key role in the onset of sequelae: Platelets are known to be involved both in the onset of a VTE episode and in the inflammatory response. This involvement is illustrated by the expression of inflammatory receptors such as TLR (toll-like receptor) 2 and TLR4.

Th aim to investigate the role of platelets in the occurrence of sequelae, mainly via their role in the inflammatory response, in Venous thromboembolic disease (VTE) patients.

Inclusion Criteria:

• Patients diagnosed with Venous ThromboEmbolic (VTE) / Proximal Deep vein thrombosis (DVT) of the lower limb and/or pulmonary embolism ≤ 72heures
• Patients are 18 years of age or older at diagnosis.
• Patients received informed written consent
• Patients benefiting from social security coverage

Exclusion Criteria:

• Diagnosis of Venous ThromboEmbolic (VTE) more than 72 hours old
• Isolated sub-segmental pulmonary embolism
• Patients on antiplatelet agents
• Patients on non-steroidal anti-inflammatory drugs (NSAIDs)
• Life expectancy > 3 months

Venous ThromboEmbolic (VTE) patients